VivoSeq
Gastroenterology

Esophagitis

49

Pipeline Programs↗

10

Active Trials↗

33

Companies Involved↗

Esophagitis is a moderately active landscape with 49 programs across 33 companies. The most active players are Phathom Pharmaceuticals, Inc., Cinclus Pharma AG, Radiation Therapy Oncology Group. 12 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

15/100

Mech. Concentration

57/100

Completion Rate

91/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Phathom Pharmaceuticals, Inc.

1 program

Phase 1C

Cinclus Pharma AG

3 programs

Phase 2Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

2 programs

Phase 2G

Galera Therapeutics, Inc.

1 program

Phase 2Z

Zeria Pharmaceutical

1 program

Phase 2B

Biotech Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Antacids

Fondation Hôpital Saint-Joseph

Mecapegfilgrastim

Tianjin Medical University Cancer Institute and Hospital

Rabeprazole ER

Eisai

L-743,872

Merck & Co.

Phase 11

Vonoprazan

Phathom Pharmaceuticals, Inc.

Phase 214

Nimotuzumab

Biotech Pharmaceutical Co., Ltd.

Mepolizumab

Glaxo Dba Glaxosmithkline

Ilaprazole

Livzon Pharmaceutical Group Inc.

S-Tenatoprazole-Na (STU-Na)

STEBA France

AZD0865

AstraZeneca

Phase 317

Famotidine

Kenvue Brands

Omeprazole

Dexcel Pharma Technologies Ltd.

Glutamine

Sanofi

Tegoprazan

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Nexium

Yooyoung Pharmaceutical Co., Ltd.

Approved12

Pantoprazole

Wyeth-Lederle Vaccines

Dexlansoprazole

Takeda

Esomeprazole

Dexcel Pharma Technologies Ltd.

Sodium Bicarbonate

Abbott

Rabeprazole

Akero Therapeutics

Analysis

Modality Breakdown

95%

Small molecule

52 of 55 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody24%Protein / enzyme12%

Small molecule leads; the ring shows all 55 classified programs, each share of the total. Modality classified for 100% of 55 pipeline programs.

Analysis

Trial Status

74

clinical trials

Completed52 · 70%
Recruiting7 · 9%
Unknown status7 · 9%
Terminated3 · 4%
Not yet recruiting2 · 3%
Suspended1 · 1%
Other2 · 3%

Clinical Trials

Trial Activity

74 trials

A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Recruiting·XXuanzhu Biopharmaceutical Co., Ltd.·Phase 3·NCT07010107·500 enrolled
Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis
Recruiting·FFirst Affiliated Hospital of Chengdu Medical College·Phase 2·NCT06392971·120 enrolled
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
Recruiting·LLivzon Pharmaceutical Group Inc.·Phase 3·NCT06850480·356 enrolled
Esomeprazole and Radiation Induced Esophagitis
Recruiting·RRush University Medical Center·Phase 2·NCT06120803·48 enrolled
Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM
Recruiting·—·N/A·NCT06955520·300 enrolled
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Recruiting·—·N/A·NCT06953986·414 enrolled
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT05267613·50 enrolled
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Active, not recruiting·Takeda logoTakeda·Phase 2·NCT02615184·76 enrolled
Spirulina Derivative for Radiation Esophagitis
Not yet recruiting·WWest China Hospital·Phase 2·NCT07324018·70 enrolled
Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
Not yet recruiting·IIndonesia University·Phase 4·NCT06720610·216 enrolled
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Completed·Eisai logoEisai·Phase 2/3·NCT00770913·337 enrolled
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
Completed·—·Phase 4·NCT00693225·91 enrolled
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00206245·1,400 enrolled
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT01669811·1,398 enrolled
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Completed·Takeda logoTakeda·N/A·NCT03214081·1,237 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)